Back

The role of NT ProBNP and Galectin 3 in the follow up of patients with primary mitral regurgitation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Treatment and outcome of mitral valve regurgitation Mitral Valve Regurgitation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Catalina Ileana Riebel

University of Medicine and Pharmacy of Cluj Napoca, Cluj Napoca (Romania)

7 More presentations in this session

Presentation thumbnail
Discussant - Treatment and outcome of mitral valve regurgitation
Presentation thumbnail
Concomitant mitral regurgitation is associated with worse outcomes after T-TEER: insights from the EuroTR registry
Doctor D. Felbel (Ulm, DE)
Abstract Video
Presentation thumbnail
Echocardiographic insights: factors influencing mitral regurgitation in fabry disease
Doctor A. Vecerova (Prague, CZ)
Abstract Video
Presentation thumbnail
Key predictors of non-interventional mitral regurgitation improvement: Insights from the SHEBAHEART registry
Doctor S. Elimeleh (Ramat Gan, IL)
Abstract Video
Presentation thumbnail
Granger causality analysis of factors driving atrial functional mitral regurgitation in atrial fibrillation
Doctor T. Avram (Cluj Napoca, RO)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Treatment and outcome of mitral valve regurgitation

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources